Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.48 |
| ▸ | THRA | P10827 | 17/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31041193 | 1.00 | THRB (0.48) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL25950026 | 0.92 | THRB (0.43) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL31041185 | 0.91 | THRB (0.41) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL282234 | 0.89 | THRB (0.51) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL1457675 | 0.89 | THRB (0.45) | THRBTHRA | |
| SCHEMBL31041196 | 0.88 | THRB (0.37) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL282100 | 0.88 | THRB (0.42) | THRBTHRAOPRK1OPRM1OPRD1 | |
| SCHEMBL4214595 | 0.88 | THRB (0.44) | THRBTHRA | |
| SCHEMBL282105 | 0.87 | THRB (0.51) | THRBTHRAOPRK1 | |
| SCHEMBL282125 | 0.87 | THRB (0.47) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339993-A1 | PREPARATION METHOD OF A CYCLIC PHOSPHONATE COMPOUND | GANNEX PHARMA CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011038207-A1 | PHOSPHORUS-CONTAINING THYROID HORMONE RECEPTOR AGONISTS AND METHODS OF USE | METABASIS THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| CN-101189248-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-101180097-A | Novel phosphinic acid-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-14 | — | — | CN | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1890768-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| CN-1882327-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2006-12-20 | — | — | CN | disclosed |
| WO-2006128056-A2 | NOVEL PHOSPHINIC ACID-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | THRB 2/4885THRA 1/4885OPRK1 1657/4885 |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885OPRK1 2455/4885 |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | THRB 1/4885THRA 3/4885OPRK1 1378/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885OPRK1 2455/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | THRB 3/4885THRA 1/4885OPRK1 2755/4885 |
| US-20230339993-A1 | PREPARATION METHOD OF A CYCLIC PHOSPHONATE COMPOUND | PHOSPHO1, PPIP5K2, PNKP | THRB 2452/4885THRA 2853/4885OPRK1 3139/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRB 41/4885THRA 14/4885OPRK1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.